Möchten Sie immer auf dem neuesten Stand bleiben?

CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the...

DENVER, CO, March 20, 2026 (GLOBE NEWSWIRE) -- The Global Down Syndrome Foundation (GLOBAL) is proud to announce that the Agency for Healthcare Research and Quality (AHRQ) systemic review of the new...

Colton, California, March 20, 2026 (GLOBE NEWSWIRE) -- California University of Science and Medicine (CUSM) today announced that the 2026 MD graduating class received residency placements as part of...

Exton, PA, March 19, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights’ Q1 2026 update of RealTime Dynamix™: Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians...

BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of...

Biotech and healthcare innovators are advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global ac

Artelo Biosciences (NASDAQ: ARTL) enters ophthalmology space with a fully funded evaluating ART27.13 in glaucoma patients.

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmology First patient enrollment anticipated in Q2 2026 SOLANA BEACH,...